

Sun Pharma Advanced Research Company Limited

Regd Office: Sun Pharma Advanced Research Centre,
Akota Road, Akota, Vadodara – 390 020. Tel. No.0265-2330815
CIN No. : L73100GJ2006PLC047837 Web Site : www.sunpharma.in

Part I Statement of Unaudited Results for the Quarter and Nine Months ended December 31, 2015

Particulars	3 Months ended			9 Months ended		in Lakhs
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	Year ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	31.03.2015
Income from Operations						
Income from Operations	3,355	4,312	3,128	12,011	11,304	15,574
Total Income from Operations	3,355	4,312	3,128	12,011	11,304	15,574
Expenses						
Cost of Materials Consumed	507	624	325	1,427	704	1,010
Employee Benefits Expense	1,342	1,362	1,150	4,069	3,389	4,579
Clinical Trials and Professional Charges	4,795	2,747	2,940	9,697	8,346	11,104
Depreciation Expense	191	189	180	562	546	724
Other Expenses	612	1,169	511	2,293	1,574	2,390
Total Expenses	7,447	6,091	5,106	18,048	14,559	19,807
Profit / (Loss) from Operations before Other Income and Finance Costs	(4,092)	(1,779)	(1,978)	(6,037)	(3,255)	(4,233)
Other Income	55	21	93	82	260	303
Profit / (Loss) from ordinary activities before Finance Costs	(4,037)	(1,758)	(1,885)	(5,955)	(2,995)	(3,930)
Finance Costs	65	16	6	86	17	22
Profit / (Loss) from ordinary activities before Tax	(4,102)	(1,774)	(1,891)	(6,041)	(3,012)	(3,952)
Tax Expense	-	-	-	-	-	-
Net Profit / (Loss) for the period	(4,102)	(1,774)	(1,891)	(6,041)	(3,012)	(3,952)
Paid-up Equity Share Capital - Face Value ` 1 each	2,367	2,367	2,367	2,367	2,367	2,367
Reserves excluding Revaluation Reserve	-	-	-	-	-	7,613
Earnings Per Share of ` 1 each – in ` (Basic and Diluted)	(1.73)	(0.75)	(0.80)	(2.55)	(1.27)	(1.67)
See accompanying Notes to the financial results						

Notes :

- The above results are as per of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and have been taken on record by the Board of Directors at its meeting held on February 3, 2016 after being reviewed by the Audit Committee and have been subjected to a limited review by the Statutory Auditors of the Company.
- The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- On September 18, 2015, the Company has filed a Draft Letter of Offer with Securities and Exchange Board of India (SEBI) for further issuance of equity shares of ` 1 each, on rights basis to the shareholders of the Company, at such ratio and price and premium as may be decided, for an amount aggregating not in excess of ` 25,000 Lakhs.
- Figures for the previous periods have been regrouped / reclassified, wherever considered necessary.

By order of the Board

Mumbai, February 3, 2016

Dilip S. Shanghvi
Chairman and Managing Director